PASenger Clinical Trial for Metastatic Prostate Cancer

When prostate cancer spreads beyond the prostate or continues to grow despite treatment that lowers testosterone, patients may need additional options. At MemorialCare Cancer Institute, specialists help patients with advanced prostate cancer weigh treatments based on their diagnosis, previous treatments and overall health. Options can include hormone therapy, chemotherapy, radiation, targeted therapies and, for eligible patients, clinical trials evaluating investigational treatments.

PASenger Phase III Clinical Trial

The PASenger study is an international Phase III clinical trial for men with metastatic castration-resistant prostate cancer, or mCRPC. This advanced form of prostate cancer has spread beyond the prostate and continues to grow despite hormone therapy.

MemorialCare Cancer Institute at Orange Coast Medical Center is one of a limited number of clinical trial sites in California offering the study.

What Treatment is Being Studied?

The study is evaluating pasritamig, an investigational bispecific T-cell engager designed to help the immune system recognize and attack prostate cancer cells. Pasritamig works by connecting T cells, the immune system’s cancer-fighting cells, with KLK2, a protein associated with prostate tissue and prostate cancer cells.

Researchers are studying whether adding pasritamig to docetaxel chemotherapy can improve outcomes for patients with metastatic castration-resistant prostate cancer compared with standard chemotherapy alone.

How is Pasritamig Designed to Work?

Pasritamig is designed to help the body's immune system find and attack prostate cancer cells. It works by connecting T cells, which are immune cells that can help fight cancer, with KLK2, a protein associated with prostate tissue and prostate cancer cells.

Who May Be Eligible?

The PASenger study is intended for a specific group of men with metastatic castration-resistant prostate cancer.

In general, it is designed for patients whose cancer has progressed despite hormone therapy and at least one next-generation hormonal treatment, but who have not yet started chemotherapy for their advanced disease.

Eligibility also depends on factors such as:

• Previous treatments
• Imaging
• Laboratory results
• Overall health

Participation in a clinical trial is voluntary. Patients who qualify and choose to participate are monitored through clinic visits, blood tests, Prostate-Specific Antigen (PSA) monitoring, imaging and safety assessments.

How Do I Find Out if I Qualify for the PASenger Study?

Patients interested in PASenger can speak with their medical oncologist or contact the MemorialCare Research team to learn more about the study and whether they may be eligible to participate. They can also call the MemorialCare Research & Clinical Trials program at (877) 696-3622.

Full study information is also available through ClinicalTrials.gov under NCT07225946.

What Happens Before I Join the Clinical Trial?

Before joining the study, patients go through a screening process to determine whether they qualify.

The research team may review:

• The patient's prostate cancer diagnosis
• Previous and current treatments
• Imaging results
• Laboratory results
• Overall health

The research team also explains what participation involves so patients can ask questions and decide whether joining the study is right for them.

What Can I Expect During the PASenger Study?

Patients who qualify and choose to participate receive care and monitoring according to the study's requirements. Because PASenger is a clinical trial, participants are followed throughout the study so the research team can monitor their health and evaluate the investigational treatment.

The research team provides each participant with information about their study schedule and what to expect during participation.

How Will I Be Monitored During the Study?

Patients who participate are monitored through:

• Clinic visits
• Blood tests
• Prostate-specific antigen (PSA) monitoring
• Imaging
• Safety assessments

These evaluations help the research team monitor participants throughout the study.

Where is the PASenger Study Offered?

The PASenger clinical trial is offered through MemorialCare Cancer Institute at Orange Coast Medical Center.

Full study information is also available through ClinicalTrials.gov under NCT07225946.

What are the Potential Benefits of Participating in the PASenger Study?

Clinical trials may give eligible patients access to investigational treatment approaches that are not otherwise available.

In the PASenger study, researchers are evaluating whether adding pasritamig to docetaxel chemotherapy can improve outcomes compared with standard chemotherapy alone.

Because pasritamig is investigational, researchers do not yet know whether an individual patient will benefit from the treatment.

What are the Possible Risks of Participating?

Investigational treatments can have known and unknown risks. Participation in a clinical trial also requires additional monitoring, which for the PASenger study includes clinic visits, blood tests, PSA monitoring, imaging and safety assessments.

Before deciding whether to participate, patients should talk with their medical oncologist and the research team about what the study involves, including possible side effects, risks, potential benefits and other treatment options.